Akero Therapeutics
BiotechUnited States
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
2
Indications↗
Distinct diseases across all programs
10
Clinical Trials↗
All sponsored trials (all statuses)
11
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
By Therapeutic Area
top 2
Gastroenterology
150%
Metabolic & Endocrine
150%
R&D Momentum
27/100
Pipeline Velocity
0/100
Trial Completion Rate
100/100
Pipeline Concentration
50/100
Pipeline Freshness
74/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Aug 8, 2026TrialA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Jul 22, 2026TrialA Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Mar 17, 2026TrialHARMONY: Efruxifermin in NASH
Jul 9, 2024FDATabloid — THIOGUANINE
Nov 10, 2023TrialA Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Jul 18, 2023FDAAciphex — ACIPHEX
Mar 4, 2022FDAAciphex — ACIPHEX
Details
Company Info
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology
Metabolic & Endocrine
Gastroenterology
Metabolic & Endocrine
Regulatory
Regulatory Timeline
20111 event
FDAMay 20
Aciphex — ACIPHEX
Application NDA020973
20122 events
FDAOct 5
Aciphex — ACIPHEX
Application NDA020973
FDAMay 8
Aciphex — ACIPHEX
Application NDA020973
20132 events
FDAApr 19
Aciphex — ACIPHEX
Application NDA020973
FDAMar 26
Aciphex — ACIPHEX SPRINKLE
Application NDA204736 (NDA)
20144 events
FDADec 19
Aciphex — ACIPHEX
Application NDA020973
FDAOct 15
Aciphex — ACIPHEX
Application NDA020973
FDAMay 8
Zontivity — ZONTIVITY
Application NDA204886 (NDA)
FDAMay 8
Zontivity — ZONTIVITY
Application NDA204886 (NDA)
20162 events
FDAOct 24
Aciphex — ACIPHEX
Application NDA020973
FDAApr 4
Aciphex — ACIPHEX
Application NDA020973
20183 events
FDAJun 7
Aciphex — ACIPHEX
Application NDA020973
FDAMay 23
Tabloid — THIOGUANINE
Application NDA012429
FDAJan 9
Aciphex — ACIPHEX
Application NDA020973
20202 events
FDANov 27
Aciphex — ACIPHEX
Application NDA020973
FDAJan 10
Valium — VALTOCO
Application NDA211635 (NDA)
20211 event
FDAApr 23
Zynlonta — ZYNLONTA
Application BLA761196 (BLA)
20221 event
FDAMar 4
Aciphex — ACIPHEX
Application NDA020973
20231 event
FDAJul 18
Aciphex — ACIPHEX
Application NDA020973
20241 event
FDAJul 9
Tabloid — THIOGUANINE
Application NDA012429
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)